

Interaction between cancer cells and myeloid cells regulates therapeutic responses to chemotherapy

Masahisa Jinushi


Institute for Genetic Medicine, Hokkaido University

Presenter disclosure information

Masahisa Jinushi, MD, PhD

No Relationships to Disclose

Myeloid cells suppress antitumor responses mediated by chemotherapy





Michele De Palma , Claire E. Lewis


Macrophage Regulation of Tumor Responses to Anticancer Therapies

Cancer Cell Volume 23, Issue 3 2013 277 - 286


The siRNA-based screening of the factors that regulate DAMPs-mediated innate immune responses



TIM-3 is a immune regulatory molecule expressed on Th1



Immune tprelance




Apoptosis
Cytokine repression

Virus specific T-cells (HCV,HBV,HIV)
T-cells in tumor and autoimmune environment




- Proliferative arrest & Apoptosis
- Suppress inflammatory cytokine induction





DC TIM-3 on antitumor response ?


High TIM-3 expression on tumor-infiltrating DCs






Percentage of TIM-3(+) DC



TIM-3 suppresses nucleic acid-mediated innate immunity






TIM-3 represses NA endocytosis in endosome mediated by HMGB-1




DC-specific TIM-3 attenuates antitumor responses of chemotherapy

- TIM3-KO BMC
- WT




TIM-3 on DCs impedes NA-mediated innate immunity in TME







Nature Immunology, 2012

The siRNA-based screening of the factors that regulate DAMPs-mediated innate immune responses





... TIM-4 as a negative regulator of innate response by myeloid cells?

TIM-4 upregulation in tumor-associated macrophages and dendritic cells





TIM-4 promotes lysosomal degradation of tumor antigens in macrophages


Phagocytosis of dying EL4 cells




LAMP1(+)*EL4*(+) fractions



TIM-4 stimulates autophagy upon engulfment of apoptotic tumor cells




AMPK pathway: key sensor for metabolic stresses



Phagocytosis of dying cells by macrophages stimulate AMPK- α activation...

apoptotic thymocytes




Bae HB et al., FASEB J. 2011 (12) 4358-68 2011


AMPK as a critical sensor
for autophagy activation...

TIM-4 interaction with AMPK activates autophagic pathways


TIM-4-AMPK- α binding (IP)




AMPK- α & ULK1 phosphorylation





Colocalization of TIM-4 and AMPK α





LC3-II activation




TIM-4-mediated activation of AMPK α /autophagy suppresses cross-priming of OVA-specific CTL responses



TIM-4/autophagy/AMPK α pathway in myeloid cells represses the *in vivo* antitumor effects of chemotherapy





Lessons and Take Home Messages

- Key points

- : We identified new immunoregulatory target (TIM-3, TIM-4) that negatively regulate therapeutic responses of anticancer drugs

- Potential impact on the field

- : Further identification of immune-mediated negative regulator may explore suitable combination between immune-target therapy and other anticancer modalities.

- Lessons learned

- : It is possible that immune cell (particularly myeloid cell)-derived factors should be ideal target to improve clinical responses of conventional anticancer strategies for cancer patients.

Acknowledgments

Hokkaido University

Research Center for Infection Associated Cancer

Muhammad Baghdadi

Akihiro Yoneda

Shigeki Chiba

Hiroko Nagao

Hironori Yoshiyama

Tsunaki Yamashina

Division of Molecular Immunology

Toshimitsu Uede

Department of Medical Oncology

Hirotoshi Dosaka-Akita

Ichiro Kinoshita

Juntendo University

Hideo Yagita

Hisaya Akiba

Kagawa University

Mitsuomi Hirashima

University of Iowa

John C. Colgan

Kumamoto University

Yoshihiro Komohara

Motohiro Takeya

University of Tokyo

Noboru Mizushima

INSERM

Benoit Viollet

